Zobrazeno 1 - 10
of 2 366
pro vyhledávání: '"programmed cell death ligand 1"'
Autor:
Shuta Ohara, Kenichi Suda, Akira Hamada, Masato Chiba, Masaoki Ito, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani
Publikováno v:
Thoracic Cancer, Vol 15, Iss 31, Pp 2229-2234 (2024)
Abstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1
Externí odkaz:
https://doaj.org/article/01fa212b64f949ff8f69a1fbe25e8ccd
Autor:
Kanatbek Mukantayev, Kanat Tursunov, Zhansaya Adish, Darkhan Kanayev, Laura Tokhtarova, Malika Nurtleu, Bisultan Abirbekov
Publikováno v:
Veterinary World, Vol 17, Iss 9, Pp 2096-2103 (2024)
Background and Aim: Bovine interleukin 15 (bIL15) is a potential immunotherapy that can block the spread of bovine leukemia virus (BLV). However, immune checkpoints that maintain body homeostasis may reduce their effectiveness. Thus, an analysis of t
Externí odkaz:
https://doaj.org/article/6c75c2480b5d4eccb2add94dd4ca3d0c
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 9, Pp 4087-4101 (2024)
Currently, the efficacy of albumin-bound paclitaxel (PTX@Alb) is still limited due to the impaired PTX@Alb accumulation in tumors partly mediated by the dense collagen distribution. Meanwhile, acquired immune resistance always occurs due to the enhan
Externí odkaz:
https://doaj.org/article/f200490f693346e19087c3bb3f423f12
Autor:
Hua Yu, Guiqing Ding, Qianyi Gong, Jinyun Ma, Yan Zhao, Yuanhua Wang, Xi Qiao, Xiaodong Cheng
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Melanoma is a highly aggressive form of skin cancer. The existence of cancer stem cells (CSCs) and tumor immune evasion are two major causes of melanoma progression, but no effective treatment has been found at present. Astragalus
Externí odkaz:
https://doaj.org/article/349c2d4fd71242f195daad21ce79381c
Publikováno v:
BMC Medical Imaging, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Programmed cell death ligand 1 (PD-L1), as a reliable predictive biomarker, plays an important role in guiding immunotherapy of lung cancer. To investigate the value of CT-based deep learning radiomics signature to predict PD-L1 e
Externí odkaz:
https://doaj.org/article/fa1b60fcc47c4e4d92f8cc229b9827b4
Publikováno v:
陆军军医大学学报, Vol 46, Iss 8, Pp 804-814 (2024)
Objective To investigate the effect of tumor-infiltrating B cells on the therapeutic efficacy of programmed death ligand-1 [PD-(L)1] inhibitors and elucidate the potential mechanisms. Methods Based on immunotherapy cohorts for melanoma patients in pu
Externí odkaz:
https://doaj.org/article/2c4c1607ffa742ceb6ea73344987d4c8
Publikováno v:
Journal of Cardiothoracic Surgery, Vol 19, Iss 1, Pp 1-6 (2024)
Abstract Background Primary cardiac angiosarcoma(PCA) has a low incidence rate and poor prognosis. Currently, no unified clinical treatment standards are available. Case presentation We report the case of a 48-year-old man presenting chest tightness,
Externí odkaz:
https://doaj.org/article/79660fedd80a463ba2b7c0e24cc28e09
Autor:
Lijuan Guo, Xiaoyi Lin, Xin Lin, Yulei Wang, Jiali Lin, Yi Zhang, Xiangqing Chen, Miao Chen, Guochun Zhang, Yifang Zhang
Publikováno v:
Cancer Pathogenesis and Therapy, Vol 2, Iss 2, Pp 91-102 (2024)
Background: Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have become integral elements within the current landscape of breast cancer treatment modalities; however, they are associated with interstitial lung dis
Externí odkaz:
https://doaj.org/article/890031ac60d04f69a18a24e162cbbfad
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundImmune checkpoint inhibitors (ICIs) are effective for non-small cell lung cancer (NSCLC) treatment, but the response rate remains low. Programmed cell death ligand 1 (PD-L1) in peripheral blood, including soluble form (sPD-L1), expression o
Externí odkaz:
https://doaj.org/article/b865103f1d694980925976ecf0a546e9
Publikováno v:
Diagnostics, Vol 14, Iss 18, p 2054 (2024)
Hepatocellular carcinoma (HCC), the most common primary liver malignancy and the sixth most common cancer globally, remains fatal for many patients with inappropriate responses to treatment. Recent advancements in immunotherapy have transformed the t
Externí odkaz:
https://doaj.org/article/71d11cbd728542c1a02493dd203e6564